Sign In
Buy VCYT
Veracyte Earnings Calls
| Release date | May 05, 2026 |
| EPS estimate | $0.340 |
| EPS actual | $0.520 |
| EPS Surprise | 52.94% |
| Revenue estimate | 130.361M |
| Revenue actual | 139.071M |
| Revenue Surprise | 6.68% |
| Release date | Feb 25, 2026 |
| EPS estimate | $0.408 |
| EPS actual | $0.530 |
| EPS Surprise | 29.81% |
| Revenue estimate | 135.786M |
| Revenue actual | 140.636M |
| Revenue Surprise | 3.57% |
| Release date | Nov 04, 2025 |
| EPS estimate | $0.320 |
| EPS actual | $0.510 |
| EPS Surprise | 59.38% |
| Revenue estimate | 135.786M |
| Revenue actual | 131.872M |
| Revenue Surprise | -2.88% |
| Release date | Aug 06, 2025 |
| EPS estimate | $0.310 |
| EPS actual | $0.440 |
| EPS Surprise | 41.94% |
| Revenue estimate | 124.353M |
| Revenue actual | 130.164M |
| Revenue Surprise | 4.67% |
Last 4 Quarters for Veracyte
Below you can see how VCYT performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 06, 2025 |
| Price on release | $23.97 |
| EPS estimate | $0.310 |
| EPS actual | $0.440 |
| EPS surprise | 41.94% |
| Date | Price |
|---|---|
| Jul 31, 2025 | $23.51 |
| Aug 01, 2025 | $23.64 |
| Aug 04, 2025 | $24.32 |
| Aug 05, 2025 | $25.01 |
| Aug 06, 2025 | $23.97 |
| Aug 07, 2025 | $27.68 |
| Aug 08, 2025 | $27.37 |
| Aug 11, 2025 | $27.99 |
| Aug 12, 2025 | $28.77 |
| 4 days before | 1.96% |
| 4 days after | 20.03% |
| On release day | 15.48% |
| Change in period | 22.37% |
| Release date | Nov 04, 2025 |
| Price on release | $36.12 |
| EPS estimate | $0.320 |
| EPS actual | $0.510 |
| EPS surprise | 59.38% |
| Date | Price |
|---|---|
| Oct 29, 2025 | $35.41 |
| Oct 30, 2025 | $35.33 |
| Oct 31, 2025 | $36.08 |
| Nov 03, 2025 | $36.45 |
| Nov 04, 2025 | $36.12 |
| Nov 05, 2025 | $46.04 |
| Nov 06, 2025 | $41.69 |
| Nov 07, 2025 | $41.70 |
| Nov 10, 2025 | $42.35 |
| 4 days before | 2.01% |
| 4 days after | 17.25% |
| On release day | 27.46% |
| Change in period | 19.60% |
| Release date | Feb 25, 2026 |
| Price on release | $35.72 |
| EPS estimate | $0.408 |
| EPS actual | $0.530 |
| EPS surprise | 29.81% |
| Date | Price |
|---|---|
| Feb 19, 2026 | $36.28 |
| Feb 20, 2026 | $35.63 |
| Feb 23, 2026 | $35.75 |
| Feb 24, 2026 | $35.69 |
| Feb 25, 2026 | $35.72 |
| Feb 26, 2026 | $38.72 |
| Feb 27, 2026 | $36.59 |
| Mar 02, 2026 | $36.01 |
| Mar 03, 2026 | $35.08 |
| 4 days before | -1.54% |
| 4 days after | -1.79% |
| On release day | 8.38% |
| Change in period | -3.31% |
| Release date | May 05, 2026 |
| Price on release | $32.97 |
| EPS estimate | $0.340 |
| EPS actual | $0.520 |
| EPS surprise | 52.94% |
| Date | Price |
|---|---|
| Apr 29, 2026 | $31.78 |
| Apr 30, 2026 | $32.92 |
| May 01, 2026 | $33.09 |
| May 04, 2026 | $33.45 |
| May 05, 2026 | $32.97 |
| May 06, 2026 | $41.19 |
| May 07, 2026 | $40.76 |
| May 08, 2026 | $40.42 |
| May 11, 2026 | $39.70 |
| 4 days before | 3.74% |
| 4 days after | 20.41% |
| On release day | 24.93% |
| Change in period | 24.92% |
Veracyte Earnings Call Transcript Summary of Q1 2026
Veracyte reported a strong start to 2026 with total revenue of $139.1M (up 21% YoY), testing revenue of $135.1M (up 26% YoY), and approximately 47,600 tests (up 17% YoY). Key growth drivers were Decipher (≈28,000 tests, +24% YoY; strength across advanced/high‑risk categories and continued expansion into bladder cancer) and Afirma (≈17,200 tests, +12% YoY; operational improvement from the V2 transcriptome lowered the no-result rate). Non‑GAAP gross margin improved to 75.7% (+350 bps YoY). Veracyte generated $35.2M cash from operations and ended the quarter with $439.1M in cash and short‑term investments. Adjusted EBITDA was $42.8M (30.8% of revenue), and GAAP net income was $28.7M. Management is raising full‑year 2026 revenue guidance to $582M–$592M (13%–14% growth) and increased adjusted EBITDA guidance to greater than 26%. Two major near‑term product catalysts are Prosigna LDT (commercial launch targeted by midyear, OPTIMA Phase III results to be presented at ASCO) and TrueMRD (WGS‑based MRD platform launching initially in muscle invasive bladder cancer by end of Q2). The company emphasized a decade-plus evidence base for Decipher, a large pipeline of prospective trials (including multiple Phase IIIs), investments in digital pathology/AI (digitizing >350,000 slides), and disciplined capital allocation focused on oncology and data‑driven extensions of their platform.
